Morbid Obesity, Type 2 Diabetes
Conditions
Brief summary
Glycaemia, insulin secretion and action in morbidly obes subjects with type 2 diabetes after sleeve gastrectomy ond Roux-en-Y gastric bypass: A randomised single centre study.
Detailed description
The Roux-en-Y gastric bypass operation combines restrictive and malabsorptive principles. It is the most commonly performed bariatric procedure worldwide (\ 50 %). Vertical (sleeve) gastrectomy on the other hand, is a purely restrictive procedure and has gained popularity and is now accepted as a valid procedure accounting for approximately five percent of the bariatric procedures performed worldwide. The remission rate of type 2 diabetes one to two years after bariatric surgery is approximately 70%. Some studies have indicate that the remission rate of type 2 diabetes is higher after gastric bypass than after sleeve gastrectomy. Other studies indicate a similar effect on the reduction in HbA1c. Weight reduction is comparable between gastric bypass and sleeve gastrectomy although some evidence suggets a larger weight loss following gastric bypass surgery. Larger weight loss can clearly contribute to somewhat greater improvement in glucose homeostasis after gastric bypass than after sleeve gastrectomy. Still, one might speculate that changes in gut hormones may contribute to higher remission rates of type 2 diabetes after gastric bypass than after sleeve gastrectomy. Improved β-cell function observed after gastric bypass surgery may be linked to higher postprandial levels of Glucagonlike peptide 1 as seen after gastric bypass surgery. Beta cell function has, to our knowledge, only been addressed in one previous study after sleeve gastrectomy, with the authors reporting an increased first-phase insulin secretion three days after the procedure. Although several studies have addressed changes in gastrointestinal hormones the incretin effect on insulin secretion after gastric bypass has been estimated in only a few studies. To the best of our knowledge the incretin effect on insulin secretion after sleeve gastrectomy remains unexplored.We are aware of four ongoing randomised controlled trials comparing the effect of gastric bypass and sleeve gastrectomy on several endpoints including weight and comorbidities (ClinicalTrial.gov identifiers: NCT00722995, NCT00356213, NCT00793143, and NCT00667706). However, these studies include both subjects with and with-out type 2 diabetes and are therefore not powered to detect between-group differences in HbA1c and beta-cell function in the diabetic patients. In conclusion, the effect of gastric bypass and sleeve gastrectomy on glycaemia is not fully elucidated. Moreover, the impact of altered beta-cell function post surgery needs to be explored. We hypothesise that greater improvement in beta-cell function after gastric bypass than after sleeve gastrectomy translates into better glycaemic control in subjects with type 2 diabetes one year after surgery.
Interventions
PROCEDUREBariatric surgery, either gastric bypass surgery or sleeve gastrectomy
Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
PROCEDURESleeve gastrecomy
Vertical sleeve gastrectomy
PROCEDUREBastric bypass
Gastric bypass surgery
Sponsors
Sykehuset i Vestfold HF
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Previously verified BMI ≥35.0 kg/m2 and current BMI ≥33.0 kg/m2 * HbA1c ≥6.5 % or use of anti-diabetic medications with HbA1c ≥6.1 % * Age ≥18 years
Exclusion criteria
* Not able to give informed consent * Previously major abdominal surgery (appendectomy, laparoscopic cholecystectomy or gynaecological procedures not included) * Severe endocrine-, heart-, lung-, liver- and kidney disease, cancer and other medical conditions associated with significantly increased risk of peri- and postoperative complications * Drug or alcohol addiction * Reduced compliance due to severe mental and psychiatric conditions * Pregnancy * Serum autoantibodies against glutamic acid decarboxylase (GAD) or tyrosine phosphatase (IA2) * Regular use (a total of 3 months cumulative use in the last 12 months) or treatment the past two months with systemic corticosteroids * Severe gastroesophageal reflux disease defined as Los Angeles classification grade \> B, Barrett's oesophagus and/or hiatus hernia \>5 cm * Elevated esophageal pressure (DCI \>5000 mmHg\*sec\*cm) and symptoms of dysphagia and/or painful swallowing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Remission of type 2 diabetes. | One year | HbA1c below or equal to 6.0 % in the absence of glucose lowering drug therapy |
| Beta-cell function | One Year | Disposition index calculated using glucose and insulin data obtained from a frequently sampled intravenous glucose tolerance test. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Insulin sensitivity | Five weeks to five years | Fasting and stimulated levels of glucose, insulin and C-peptide after an oral glucose load will be used for the calculation of insulin sensitivity. |
| Anti-diabetic medication | Five weeks to five years | Use of glucose lowering agents |
| Body weight | Five weeks to five years | Body weight (kg and kg/m2) |
| Body composition | Five weeks to five years | Measured by DEXA and bioelectrical impedance analysis |
| Blood pressure | Five weeks to five years | Resting and 24-h ambulatory systolic and diastolic blood pressure |
| Pulse wave velocity | Five weeks to five years | The Sphygmocor system (Artcor, Sidney, Australia) and a single high-fidelity applanation tonometer (Millar®) will be used to measure pulse wave velocity. |
| Lipidemia | Five weeks to five years | Cholesterol and triglyceride levels |
| Obstructive sleep apnoea | Five weeks to five years | The ApneaLink Plus was used for the calculation of apnoeas and hypopnoeas during sleep. |
| Proteinuria | Five weeks to five years | Urine protein-to-creatinine and albumin-to-creatinine ratios |
| Gastroesophageal reflux disease | One to five years | Gastroesophageal reflux disease will be diagnosed using upper endoscopy, 24 hour intra-oesophageal pH monitoring and symptom scores. |
| Glycaemic control | Five weeks to five years | HbA1c |
| Fatty liver disease | One to five years | MRI (Siemens Aera 1.5 T) and Chemical Shift Imaging18 will be used to quantify the fat-fraction content of the liver. |
| Gut microbiota | One to five years | Microbial composition and diversity and quantification of organic acids and DNA extraction and metagenome data analysis. |
| Physical activity | Five weeks to five years | Measured and self-reported physical activity |
| Energy intake and eating behaviour | Five weeks to five years | Food frequency questionnaire, food tolerance questionnaire, power of food scale and binge eating scale |
| Health related quality of life | Five weeks to five years | Short Form Quality of Life questionnaire (SF-36) v. 2.0 |
| Obesity-related symptoms | Five weeks to five years | Impact on Weight Questionnaire IWQOL-Lite and Weight-Related Symptom Measure (WRSM) |
| Psychological distress | Five weeks to five years | Beck Depression Inventory |
| Bone mineral density | Five weeks to five years | DEXA scan |
| Dumping syndrome | Five weeks to five years | Arts' questionnaire |
| Vitamin and mineral deficiencies | Five weeks to five years | Vitamin (B1, B9, B12, D) and mineral (calcium, iron) levels in blood. |
| Gastroesophageal motility disorders | One to five years | High-resolution manometry |
| Insulin secretion | Five weeks to five years | Fasting and stimulated levels of glucose, insulin, C-peptide and proinsulin after an oral glucose load will be used for the calculation of insulin secretion. |
Countries
Norway
Outcome results
None listed